After intratumoral or postsurgical administration, the lipolysis of cancer cells promotes the release of RA and pDox from the engineered adipocytes, exerting antitumor effect while downregulating programmed cell death‐ligand 1 (PD‐L1) expression, favoring CD4+ and CD8+ T lymphocyte‐mediated immunotherapy. Here, CD274 is linked to cancer.